Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_416767ab092e9c11cec92cb1ff53c356 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e6947430e0e3b673d72f068a87de145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6e88ed84a8af11c707d7f6847a00ffa |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-06 |
filingDate |
2000-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10e8ebbd4e807ee8536980fa88569292 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94fee63c2aee58b86b602127455a7285 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c31b03abbf3abaab24a9efd48463b89c |
publicationDate |
2001-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-0145686-A2 |
titleOfInvention |
Formulations of adenosine a1 agonists |
abstract |
The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, a adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and an EP1 antagonist or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02102392-A1 |
priorityDate |
1999-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |